Cancer drug resistance: an evolving paradigm
The DOI matches its Crossref record; 176 of the 178 references it cites were found in a registry or an index.
Abstract
Resistance to chemotherapy and molecularly targeted therapies is a major problem facing current cancer research. The mechanisms of resistance to 'classical' cytotoxic chemotherapeutics and to therapies that are designed to be selective for specific molecular targets share many features, such as alterations in the drug target, activation of prosurvival pathways and ineffective induction of cell death. With the increasing arsenal of anticancer agents, improving preclinical models and the advent of powerful high-throughput screening techniques, there are now unprecedented opportunities to understand and overcome drug resistance through the clinical assessment of rational therapeutic drug combinations and the use of predictive biomarkers to enable patient stratification.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“There is much value in doing so because the tumor heterogeneity confers unique advantages for the tumor, such as an inherent resistance to therapy [10,11].”
From Microfluidic modelling of the tumor microenvironment for anti-cancer drug development (2019) · cites this paper as [10]
In the citing paper
“This is not surprising, since decades of research on targeted cancer therapy have shown that the majority of patients who respond well to initial treatment develop resistance.57, 58, 59, 60”
From Overcoming Resistance to Drugs Targeting KRAS Mutation (2020) · cites this paper as [57]
In the citing paper
“In the clinic, intrinsic and acquired resistance may co-exist and intertwine in the same patient treated with K-RasG12C-targeted therapies.57,61”
From Overcoming Resistance to Drugs Targeting KRAS Mutation (2020) · cites this paper as [57]
In the citing paper
“Genomic heterogeneity arising from a variety of co-occurring mutations may contribute to the heterogeneous extent of adaptive resistance across KRAS mutant cancers.57,58”
From Overcoming Resistance to Drugs Targeting KRAS Mutation (2020) · cites this paper as [57]
In the citing paper
“In the clinic, the persister state most closely corresponds to minimal residual disease from which relapse can occur if treatment is discontinued or if acquired drug resistance develops in response to continuous therapy.”
From Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer (2021) · cites this paper as [8]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Multidrug resistance in cancer: role of ATP–dependent transporters
Gottesman, M. M., Fojo, T., & Bates, S. E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc706 · Cited by 5,536
5-Fluorouracil: mechanisms of action and clinical strategies
Longley, D. B., Harkin, D. P., & Johnston, P. G. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1074 · Cited by 5,332
Self-citationNew Perspectives in Cell Adhesion: RGD and Integrins
Ruoslahti, E., & Pierschbacher, M. D. (1987) · Science · doi:10.1126/science.2821619 · Cited by 4,865
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964
Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Sequist, L. V., Waltman, B. A., Dias-Santagata, D., Digumarthy, S., Turke, A. B., Fidias, P., Bergethon, K., Shaw, A. T., Gettinger, S., Cosper, A. K., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002003 · Cited by 3,499
Cited by
Items 601–700 of 1,016
Shin, W. S., Lee, M.-G., Verwilst, P., Lee, J. H., Chi, S.-G., & Kim, J. S. (2016) · Chemical Science · doi:10.1039/c6sc02236g · Cited by 95
A miR-20a/MAPK1/c-Myc regulatory feedback loop regulates breast carcinogenesis and chemoresistance
Si, W., Shen, J., Du, C., Chen, D., Gu, X., Li, C., Yao, M., Pan, J., Cheng, J., Jiang, D., et al. (2017) · Cell Death and Differentiation · doi:10.1038/cdd.2017.176 · Cited by 101
“tant for patients with advanced and metastatic tumors that cannot undergo surgery.(3) Because of the high cost of targeted”
BackgroundLiu, Y., Cao, Y., Pan, X., Shi, M., Wu, Q., Huang, T., Jiang, H., Li, W., & Zhang, J. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0522-0 · Cited by 94
CCL20 triggered by chemotherapy hinders the therapeutic efficacy of breast cancer
Chen, W., Qin, Y., Wang, D., Zhou, L., Liu, Y., Chen, S., Yin, L., Xiao, Y., Yao, X.-H., Yang, X., et al. (2018) · PLoS Biology · doi:10.1371/journal.pbio.2005869 · Cited by 101
Wang, Y., Yang, M., Qian, J., Xu, W., Wang, J., Hou, G., Ji, L., & Suo, A. (2018) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2018.09.035 · Cited by 94
Wang, Y., Zhang, J., Ren, S., Sun, D., Huang, H.-Y., Wang, H., Jin, Y., Li, F., Zheng, C., Yang, L., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.06.026 · Cited by 95
Yang, C., Tian, C., Hoffman, T. E., Jacobsen, N. K., & Spencer, S. L. (2021) · Nature Communications · doi:10.1038/s41467-021-21549-x · Cited by 94
Near-infrared light-triggered nano-prodrug for cancer gas therapy
Liu, R., Peng, Y., Lu, L., Peng, S., Chen, T., & Zhan, M. (2021) · Journal of Nanobiotechnology · doi:10.1186/s12951-021-01078-x · Cited by 97
“In fact, it is also a therapeutic gas transmitter, and can cause oxidative damage to tumor cells by exhausting glutathione in the tumor microenvironment and destroying the membrane structure [218, 219].”
BackgroundBRD4 Inhibitor Inhibits Colorectal Cancer Growth and Metastasis
Hu, Y., Zhou, J., Ye, F., Xiong, H., Peng, L., Zheng, Z., Xu, F., Cui, M., Wei, C., Wang, X., et al. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms16011928 · Cited by 103
“be promoting pathways that lead to tumor resistance, through the activation of pro-inflammatory and anti-apoptotic factors [2–4].”
BackgroundA New View of Pathway-Driven Drug Resistance in Tumor Proliferation
Nussinov, R., Tsai, C., & Jang, H. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.02.001 · Cited by 102
“The tumor microenvironment [86] and drug metabolism [82] can be involved via oxidative stress.”
BackgroundRed Blood Cells for Drug Delivery
Yan, J., Yu, J., Wang, C., & Gu, Z. (2017) · Small Methods · doi:10.1002/smtd.201700270 · Cited by 97
Addressing intra-tumoral heterogeneity and therapy resistance
Rybinski, B., & Yun, K. (2016) · Oncotarget · doi:10.18632/oncotarget.11875 · Cited by 108
“In addition, proximity to stromal cells such as immune cells and fibroblasts, which can function in paracrine manners to support cancer cell proliferation and survival [4, 5], also differs among cancer cells.”
BackgroundInfluentialOxidative Stress, Nrf2, and Epigenetic Modification Contribute to Anticancer Drug Resistance
Kang, K. A., & Hyun, J. W. (2017) · Toxicological Research · doi:10.5487/tr.2017.33.1.001 · Cited by 95
“The mechanisms underlying the development of anticancer drug resistance are complex and often involve activation of antioxidant or detoxifying enzymes (5,6).”
BackgroundCostea, T., Vlad, O., Miclea, L. C., Ganea, C., Szöllõsi, J., & Mocanu, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21020401 · Cited by 101
“Moreover, other factors are also involved in EMT activation such as growth factors (FGF, EGF, TGF-β), adhesion molecules (ICAM-1), signaling pathways (NF-κB, Wnt/β-catenin, Notch), overexpression of EMT transcription factors (slug, snail) and members of heat-shock proteins family (such as glucose regulated protein 78…”
BackgroundTurning liabilities into opportunities: Off-target based drug repurposing in cancer
Palve, V. C., Liao, Y., Rix, L. L. R., & Rix, U. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.02.003 · Cited by 103
Gurung, A. B., Ali, M. A., Lee, J., Farah, M. A., & Al‐Anazi, K. M. (2021) · PLoS ONE · doi:10.1371/journal.pone.0254035 · Cited by 98
“It has been advocated that the challenges due to intrinsic and acquired resistance to anti-cancer drugs can be mitigated through multi-target therapy approaches [42, 43].”
RetractedElectrophilic warheads in covalent drug discovery: an overview
Péczka, N., Orgován, Z., Ábrányi‐Balogh, P., & Keserű, G. M. (2022) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2022.2034783 · Cited by 99
“Resistance mutations are great nuisance in drug discovery, where the proteins change their binding site resulting that former non-covalent interactions are no longer effective [14].”
BackgroundSelf‐Assembled Aza‐Boron‐Dipyrromethene for Ferroptosis‐Boosted Sonodynamic Therapy
You, C., Li, X., Wang, D., Chen, H., Liang, L., Chen, Y., Zhao, Y., & Xiang, H. (2022) · Angewandte Chemie International Edition · doi:10.1002/anie.202210174 · Cited by 96
Chen, X., Li, Q., Liu, X., Liu, C., Liu, R., Rycaj, K., Zhang, D., Liu, B., Jeter, C. R., Calhoun‐Davis, T., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2956 · Cited by 92
“, intrinsic and acquired, underlie the resistance of cancer cells to both general and targeted anticancer therapeutics (40).”
Yamaguchi, N., Weinberg, E. M., Nguyen, A., Liberti, M. V., Goodarzi, H., Janjigian, Y. Y., Paty, P. B., Saltz, L. B., Kingham, T. P., Loo, J. M., et al. (2019) · eLife · doi:10.7554/elife.52135 · Cited by 91
Hippo pathway mediates resistance to cytotoxic drugs
Gujral, T. S., & Kirschner, M. W. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1703096114 · Cited by 91
“Adaptive (nongenetic or regulatory) responses, such as increased expression of the therapeutic target or activation of compensatory pathways, can also influence drug efficacy over time (1).”
BackgroundHauser, K., Negron, C., Albanese, S. K., Ray, S., Steinbrecher, T., Abel, R., Chodera, J. D., & Wang, L. (2018) · Communications Biology · doi:10.1038/s42003-018-0075-x · Cited by 94
“, induction of splice 32 variants [16], or alleviation of feedback [17]), inherent or acquired missense mutations in the kinase domain 33 of the target of therapy are a major form of resistance to tyrosine kinase inhibitors (TKI) [10, 18, 19].”
Combining Allosteric and Orthosteric Drugs to Overcome Drug Resistance
Ni, D., Li, Y., Qiu, Y., Pu, J., Lu, S., & Zhang, J. (2020) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2020.02.001 · Cited by 95
Multiple low dose therapy as an effective strategy to treat EGFR inhibitor-resistant NSCLC tumours
Fernandes Neto, J. M., Nadal, E., Bosdriesz, E., Ooft, S. N., Farre, L., McLean, C., Klarenbeek, S., Jurgens, A., Hagen, H., Wang, L., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16952-9 · Cited by 92
Wang, Z., Wang, N., Li, W., Liu, P., Chen, Q., Situ, H., Zhong, S., Guo, L., Lin, Y. H., Shen, J., et al. (2014) · Carcinogenesis · doi:10.1093/carcin/bgu155 · Cited by 91
“In the last decade, the ATP-binding cassette protein superfamily has received much attention, particularly the proteins ATP-binding cassette subfamily B member 1 (ABCB1), ATP-binding cassette subfamily G member 2 (ABCG2) and ATP-binding cassette subfamily C member 1 (6).”
BackgroundHu, S., HUANG, L., Meng, L., Sun, H., Zhang, W., & Xu, Y. (2015) · Molecular Medicine Reports · doi:10.3892/mmr.2015.4269 · Cited by 98
“It is well-known that the phosphoinositide 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) and the mitogen-activated protein kinase (MAPK)/MAPK kinase (MEK) signaling pathways have important roles in tumor progression and drug resistance in various types of cancer (4).”
Morphological single cell profiling of the epithelial–mesenchymal transition
Leggett, S. E., Sim, J. Y., Rubins, J. E., Neronha, Z. J., Williams, E. K., & Wong, I. Y. (2016) · Integrative Biology · doi:10.1039/c6ib00139d · Cited by 109
A Transformable Chimeric Peptide for Cell Encapsulation to Overcome Multidrug Resistance
Zhang, C., Liu, L., Qiu, W., Zhang, Y., Song, W., Zhang, L., Wang, S., & Zhang, X. (2018) · Small · doi:10.1002/smll.201703321 · Cited by 90
The lncRNA BORG facilitates the survival and chemoresistance of triple-negative breast cancers
Gooding, A. J., Zhang, B., Gunawardane, L. S., Beard, A., Valadkhan, S., & Schiemann, W. P. (2018) · Oncogene · doi:10.1038/s41388-018-0586-4 · Cited by 94
Circular RNAs in drug resistant tumors
Hua, X., Sun, Y., Chen, J., Wu, Y., Sha, J., Han, S., & Zhu, X. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109233 · Cited by 97
Liang, X. Q., Li, F., Chen, J.-X., Li, J., Wu, H., Li, S., Song, J., & Liu, Q. (2020) · Briefings in Bioinformatics · doi:10.1093/bib/bbaa312 · Cited by 95
MLACP 2.0: An updated machine learning tool for anticancer peptide prediction
Phan, L. T., Park, H. W., Pitti, T., Madhavan, T., Jeon, Y.-J., & Manavalan, B. (2022) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2022.07.043 · Cited by 87
“Hence, cancer therapy must focus primarily on limiting the proliferation of cancer cells and inhibiting their spread [4].”
BackgroundEbrahimi, N., Afshinpour, M., Fakhr, S. S., Kalkhoran, P. G., Shadman-Manesh, V., Adelian, S., Beiranvand, S., Rezaei-Tazangi, F., Khorram, R., Hamblin, M. R., et al. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.103920 · Cited by 91
Modulation of redox homeostasis: A strategy to overcome cancer drug resistance
Yang, L., Zhang, X., Wang, Z., Li, B., & Zhu, H. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1156538 · Cited by 116
“, gene mutations), while acquired resistance is caused by changes in tumor cells during treatment, including drug target expression, post-translational modification, and activation of bypass signaling (Holohan et al., 2013; Li et al., 2020).”
BackgroundImpact of Membrane Drug Transporters on Resistance to Small-Molecule Tyrosine Kinase Inhibitors
Neul, C., Schaeffeler, E., Sparreboom, A., Laufer, S., Schwab, M. G., & Nies, A. T. (2016) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.08.003 · Cited by 101
“For decades multidrug resistance has been well known as a cause of poor response to cancer chemotherapy [15], and therefore might also contribute to TKI-related molecularly targeted drug resistance [9,10].”
BackgroundResultDual Role of Mitophagy in Cancer Drug Resistance
Chen, Y., & Li, T. (2018) · Anticancer Research · doi:10.21873/anticanres.12266 · Cited by 105
Li, Y., Bui, Q. N., Duy, L. T., Yang, H. Y., & Lee, D. S. (2018) · Biomacromolecules · doi:10.1021/acs.biomac.8b00195 · Cited by 95
Self‐Assembled Nanoparticles from Phenolic Derivatives for Cancer Therapy
Dai, Y., Guo, J., Wang, T., Ju, Y., Mitchell, A. J., Bonnard, T., Cui, J., Richardson, J. J., Hagemeyer, C. E., Alt, K., et al. (2017) · Advanced Healthcare Materials · doi:10.1002/adhm.201700467 · Cited by 90
Resistance to cancer chemotherapeutic drugs is determined by pivotal microRNA regulators.
Geretto, M., Pulliero, A., Rosano, C., Zhabayeva, D., Bersimbaev, R. I., & Izzotti, A. (2017) · PubMed Central · Cited by 108
Yu, L., Jing, R., Liu, F., Luo, J., & Li, Y. (2020) · Molecular Therapy Nucleic Acids · doi:10.1016/j.omtn.2020.10.005 · Cited by 90
“6 To combat this deadly disease and prolong the lives of patients, more and more attention is being paid to the discovery and design of novel anticancer agents in recent years.”
BackgroundXie, R., Ruan, S., Liu, J., Qin, L., Yang, C., Tong, F., Lei, T., Shevtsov, M., Gao, H., & Qin, Y. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.120891 · Cited by 87
Qin, H., Leng, J., Zhang, C., Jantan, I., Amjad, M. W., Sher, M., Hassan, M. N. U., Hussain, M. A., & Bukhari, S. N. A. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00276 · Cited by 89
The Unfolded Protein Response in Breast Cancer
McGrath, E. P., Logue, S. E., Mnich, K., Deegan, S., Jäger, R., Gorman, A. M., & Samali, A. (2018) · Cancers · doi:10.3390/cancers10100344 · Cited by 95
“primary goal for the breast cancer field [5].”
BackgroundWang, T., Liu, J., Luo, X., Hu, L., & Lu, H. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107824 · Cited by 96
Leto, S. M., & Trusolino, L. (2014) · Journal of Molecular Medicine · doi:10.1007/s00109-014-1161-2 · Cited by 87
“of ongoing treatment that was initially effective and can be caused bymutations arising during treatment as well as through other various adaptive nongenetic responses [15, 16].”
Unexpected Off-Targets and Paradoxical Pathway Activation by Kinase Inhibitors
Hantschel, O. D. (2015) · ACS Chemical Biology · doi:10.1021/cb500886n · Cited by 93
Necroptosis: A new way of dying?
Hanson, B. (2016) · Cancer Biology & Therapy · doi:10.1080/15384047.2016.1210732 · Cited by 86
“Before the discovery of necroptosis as a new way of dying, apoptosis was the intended fate for cancer cells but resistance to this type of cell death has since emerged.(104) Amajor driver of apoptosis resistance is the increased expression of cIAPs in a wide range of tumor cells but additional mechanisms also exist to…”
BackgroundTumour microenvironment-responsive semiconducting polymer-based self-assembling nanotheranostics
Yáng, Z., Dai, Y., Shan, L., Shen, Z., Wang, Z., Yung, B. C., Jacobson, O., Liu, Y., Tang, W., Wang, S., et al. (2018) · Nanoscale Horizons · doi:10.1039/c8nh00307f · Cited by 87
Nanoparticles‐Mediated Combination Therapies for Cancer Treatment
Shrestha, B., Tang, L., & Romero, G. (2019) · Advanced Therapeutics · doi:10.1002/adtp.201900076 · Cited by 98
Resveratrol As A Natural Regulator Of Autophagy For Prevention And Treatment Of Cancer
Tian, Y., Song, W., Li, D., Cai, L., & Zhao, Y. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s213043 · Cited by 90
PROTACs as Potential Therapeutic Agents for Cancer Drug Resistance
Sun, X., & Rao, Y. (2019) · Biochemistry · doi:10.1021/acs.biochem.9b00848 · Cited by 93
Pucelik, B., Sułek, A., Borkowski, M., Barzowska, A., Kobielusz, M., & Dąbrowski, J. M. (2022) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.2c01100 · Cited by 91
Tiram, G., Segal, E., Krivitsky, A., Shreberk-Hassidim, R., Ferber, S., Ofek, P., Udagawa, T., Edry, L., Shomron, N., Roniger, M., et al. (2016) · ACS Nano · doi:10.1021/acsnano.5b06189 · Cited by 86
Intelligent polymeric micelles for multidrug co-delivery and cancer therapy
Yu, G., Ning, Q., Mo, Z., & Tang, S. (2019) · Artificial Cells Nanomedicine and Biotechnology · doi:10.1080/21691401.2019.1601104 · Cited by 90
“On the one hand, poor solubility, serious side effect and multidrug resistance (MDR) had been identified the “Achilles’ heel” of chemotherapy drugs [2,3].”
BackgroundMeasurement of oxidatively induced DNA damage and its repair, by mass spectrometric techniques
Dizdaroglu, M., Coskun, E., & Jaruga, P. (2015) · Free Radical Research · doi:10.3109/10715762.2015.1014814 · Cited by 88
“In the future, DNA repair proteins as biomarkers and therapy targets may be incorporated into routine cancer therapy, and may contribute to the development of the concept of personalized therapy [181-185].”
BackgroundLee, J., Choi, H., Yun, M., Kang, Y. J., Jung, J., Ryu, Y., Kim, T. Y., Cha, Y., Cho, H., Min, J., et al. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201505964 · Cited by 89
Plasticity of Cancer Cell Invasion—Mechanisms and Implications for Therapy
Boekhorst, V. T., & Friedl, P. (2016) · Advances in cancer research · doi:10.1016/bs.acr.2016.07.005 · Cited by 101
Lim, W. Q., Phua, S. Z. F., Xu, H. V., Sreejith, S., & Zhao, Y. (2016) · Nanoscale · doi:10.1039/c5nr07853a · Cited by 90
Han, J., Jun, Y., Ys, K., Hoang, H.-H., Jung, Y., Kim, S., Kim, J., Austin, R. H., Lee, S., & Park, S. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1614898113 · Cited by 87
“A problem in chemotherapy is that cancer patients frequently develop drug resistance, limiting the survival benefit of therapeutic agents to the short term; this is true of traditional chemotherapeutic reagents as well as so-called second generation reagents that target specific oncogenes (1).”
BackgroundncDR: a comprehensive resource of non-coding RNAs involved in drug resistance
Dai, E., Yang, F., Wang, J., Zhou, X., Song, Q., An, W., Wang, L., & Jiang, W. (2017) · Bioinformatics · doi:10.1093/bioinformatics/btx523 · Cited by 85
“Overwhelming evidence has demonstrated that drug resistance is the primary cause of clinical treatment failure, because patients who have similar clinical characteristics are usually treated by standard protocols without considering individual responses (Holohan et al., 2013). Two kinds of non-coding RNA (ncRNA), both…”
BackgroundZhang, Y., Chen, S., Wei, C., Rankin, G. O., Ye, X., & Chen, Y. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.01.084 · Cited by 87
“Therefore, inducing apoptosis to overcome oncogenic resistance is one of the potential therapeutics for cancer patients [3, 7].”
BackgroundCell-to-Cell Heterogeneity in p38-Mediated Cross-Inhibition of JNK Causes Stochastic Cell Death
Miura, H., Kondo, Y., Matsuda, M., & Aoki, K. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.08.020 · Cited by 88
Dhiman, N., Kingshott, P., Sümer, H., Sharma, C. S., & Rath, S. N. (2019) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2019.02.070 · Cited by 90
Tackling drug resistance with efflux pump inhibitors: from bacteria to cancerous cells
Christena, L. R., Subramaniapillai, S. G., Ulaganathan, V., & Nagarajan, S. (2019) · Critical Reviews in Microbiology · doi:10.1080/1040841x.2019.1607248 · Cited by 93
“Drug resistance plagues from resistance posed by infectious agents (microbes), to resistance for chemotherapeutic agents displayed by tumorous cells (Holohan et al. 2013; Housman et al. 2014).”
BackgroundSong, C., Li, Y., Li, T., Yang, Y., Huang, Z., de la Fuente, J. M., Ni, J., & Cui, D. (2020) · Advanced Functional Materials · doi:10.1002/adfm.201906309 · Cited by 86
Zhang, R., Li, S., Liu, L., Yang, J., Huang, G., & Sang, Y. (2020) · Oncogenesis · doi:10.1038/s41389-020-0229-9 · Cited by 89
Ni, Z., Wang, B., Dai, X., Ding, W., Yang, T., Li, X., Lewin, S. J., Xu, L., Lian, J., & He, F. (2014) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2014.02.012 · Cited by 87
“It is well known that autophagy is closely related to the therapeutic resistance of cancer [20].”
BackgroundAltıntop, M. D., Özdemır, A., Turan‐Zitouni, G., Ilgın, S., Atlı, Ö., Demirel, R., & Kaplancıklı, Z. A. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.12.055 · Cited by 87
Ritter, A., Friemel, A., Fornoff, F., Adjan, M., Solbach, C., Yuan, J., & Louwen, F. (2015) · Oncotarget · doi:10.18632/oncotarget.5922 · Cited by 95
“Consequently, the EMT-like MCF-7 cells show a reinforced migration and invasion potential, and confer resistance to Plk1 inhibitors BI 2536 and BI 6727, in accordance with previous reports showing resistance to other chemotherapeutic drugs [56].”
ResultFarooqi, S. I., Arshad, N., Channar, P. A., Perveen, F., Saeed, A., Larik, F. A., & Javeed, A. (2018) · Journal of Photochemistry and Photobiology B Biology · doi:10.1016/j.jphotobiol.2018.10.006 · Cited by 85
Liu, J. F., Ray-Coquard, I. L., Selle, F., Poveda, A. M., Cibula, D., Hirte, H. W., Hilpert, F., Raspagliesi, F., Gladieff, L., Harter, P., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.1891 · Cited by 88
“desensitized to therapy by upregulating autocrine or paracrine growth factors that activate antiapoptotic signaling pathways.(7-9) Notably, heregulin (HRG) -driven ErbB3 signaling mediates insensitivity to a broad range of therapies by activating the phosphoinositide 3-kinase (PI3K)/Akt signaling pathway.”
BackgroundRui, M., Xin, Y., Li, R., Ge, Y., Feng, C., & Xu, X. (2016) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6b00732 · Cited by 85
Lin, K., Rutter, J. C., Xie, A., Pardieu, B., Winn, E. T., Bello, R. D., Forget, A., Itzykson, R., Ahn, Y.-R., Dai, Z., et al. (2020) · Nature Genetics · doi:10.1038/s41588-020-0590-9 · Cited by 97
HDAC Inhibitors: Dissecting Mechanisms of Action to Counter Tumor Heterogeneity
Karagiannis, D., & Rampias, T. N. (2021) · Cancers · doi:10.3390/cancers13143575 · Cited by 95
Breast cancer resistance to chemotherapy: When should we suspect it and how can we prevent it?
Prihantono, P., & Faruk, M. (2021) · Annals of Medicine and Surgery · doi:10.1016/j.amsu.2021.102793 · Cited by 99
Nanomedicine‐Enabled/Augmented Cell Pyroptosis for Efficient Tumor Nanotherapy
Zhang, Z., Zhou, Y., Zhao, S., Ding, L., Chen, B., & Chen, Y. (2022) · Advanced Science · doi:10.1002/advs.202203583 · Cited by 89
Clinical translation of wireless soft robotic medical devices
Wang, T., Wu, Y., Yıldız, E., Kanyas, S., & Sitti, M. (2024) · Nature Reviews Bioengineering · doi:10.1038/s44222-024-00156-7 · Cited by 102
“intracellular barriers, such as lysosomes or endosomes, which can degrade or sequester drugs before they reach their intended intracellular targets 106 .”
Translational Horizons in the Tumor Microenvironment: Harnessing Breakthroughs and Targeting Cures
Sun, Y. (2015) · Medicinal Research Reviews · doi:10.1002/med.21338 · Cited by 83
FLIP as a therapeutic target in cancer
Humphreys, L. M., Espona‐Fiedler, M., & Longley, D. B. (2018) · FEBS Journal · doi:10.1111/febs.14523 · Cited by 93
Self-citationCancer nanomedicine: focus on recent developments and self-assembled peptide nanocarriers
Raza, F., Zafar, H., You, X., Asifullah, K., Wu, J., & Ge, L. (2019) · Journal of Materials Chemistry B · doi:10.1039/c9tb01842e · Cited by 87
Senescence-Associated Pro-inflammatory Cytokines and Tumor Cell Plasticity
Vernot, J. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.00063 · Cited by 86
Supramolecular combination chemotherapy: a pH-responsive co-encapsulation drug delivery system
Chen, J., Zhang, Y., Meng, Z., Guo, L., Yuan, X., Zhang, Y., Chai, Y., Sessler, J. L., Meng, Q., & Li, C. (2020) · Chemical Science · doi:10.1039/d0sc01756f · Cited by 85
DUSP16 promotes cancer chemoresistance through regulation of mitochondria-mediated cell death
Low, H. B., Wong, Z. L., Wu, B., Kong, L. R., Png, C. W., Cho, Y.-L., Li, C., Xiao, F., Xin, X., Yang, H. H., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22638-7 · Cited by 88
Toward a Cancer Drug of Fungal Origin
Kornienko, A., Evidente, A., Vurro, M., Mathieu, V., Cimmino, A., Evidente, M., van Otterlo, W. A. L., Dasari, R., Lefranc, F., & Kiss, R. (2015) · Medicinal Research Reviews · doi:10.1002/med.21348 · Cited by 89
Indirubin and Indirubin Derivatives for Counteracting Proliferative Diseases
Blažević, T., Heiß, E. H., Atanasov, A. G., Breuss, J. M., Dirsch, V. M., & Uhrín, P. (2015) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2015/654098 · Cited by 87
“Such competence of indirubins to influence multilaterally several cellular signaling networks and metabolism strongly suggests that indirubins could be used as drugs, either alone or in combination with conventional antineoplastic agents, to overcome multidrug resistance, which represents a major impediment to the eff…”
BackgroundKim, B., Lee, C., Lee, E. S., Shin, B. S., & Youn, Y. S. (2016) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2016.05.005 · Cited by 84
Cancer stem cells, metabolism, and therapeutic significance
Yang, M., Liu, P., & Huang, P. (2016) · Tumor Biology · doi:10.1007/s13277-016-4945-x · Cited by 85
Bach, D., Kim, D., Bae, S. Y., Kim, W. K., Hong, J., Lee, H., Rajasekaran, N., Kwon, S., Fan, Y., Luu, T.-T.-T., et al. (2018) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2018.03.011 · Cited by 83
Deng, Y., Käfer, F. H., Chen, T., Jin, Q., Ji, J., & Agarwal, S. (2018) · Small · doi:10.1002/smll.201802420 · Cited by 82
Yang, C., Chan, K. K., Xu, G., Yin, M., Lin, G., Wang, X., Lin, W., Birowosuto, M. D., Zeng, S., Ogi, T., et al. (2018) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.8b16168 · Cited by 83
Halim, C. E., Xinjing, S. L., Fan, L., Vitarbo, J. B., Arfuso, F., Tan, C. H., Narula, A. S., Kumar, A. P., Sethi, G., & Ahn, K. S. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104327 · Cited by 83
Engineered collagen-binding serum albumin as a drug conjugate carrier for cancer therapy
Sasaki, K., Ishihara, J., Ishihara, A., Miura, R., Mansurov, A., Fukunaga, K., & Hubbell, J. A. (2019) · Science Advances · doi:10.1126/sciadv.aaw6081 · Cited by 83
Vitamin C induces ferroptosis in anaplastic thyroid cancer cells by ferritinophagy activation
Wang, X., Xu, S., Zhang, L., Cheng, X. F., Yu, H., Bao, J., & Lu, R. (2021) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2021.02.126 · Cited by 89
Cross-resistance and drug sequence in prostate cancer
Buck, S. A. J., Koolen, S. L. W., Mathijssen, R. H. J., de Wit, R., & van Soest, R. J. (2021) · Drug Resistance Updates · doi:10.1016/j.drup.2021.100761 · Cited by 90
Dual-drug codelivery nanosystems: An emerging approach for overcoming cancer multidrug resistance
Gong, J., Shi, T., Liu, J., Pei, Z., Liu, J., Ren, X., Li, F., & Qiu, F. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114505 · Cited by 86
Guo, Y., Ashrafizadeh, M., Tambuwala, M. M., Ren, J., Orive, G., & Yu, G. (2024) · Drug Discovery Today · doi:10.1016/j.drudis.2024.104161 · Cited by 85
Molecular Oncology of Breast Cancer
Joshi, H. N., & Press, M. F. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-35955-9.00022-2 · Cited by 97
Altıntop, M. D., Sever, B., Çiftçi, G. A., Turan‐Zitouni, G., Kaplancıklı, Z. A., & Özdemır, A. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.06.049 · Cited by 82
Ahamad, M. N., Iman, K., Raza, M. K., Kumar, M., Ansari, A., Ahmad, M., & Shahid, M. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.103561 · Cited by 92
The Role of Exosomal microRNA in Cancer Drug Resistance
Guo, Q.-R., Wang, H., Yan, Y.-D., Liu, Y., Su, C., Chen, H., Yan, Y., Adhikari, R., Wu, Q., & Zhang, J. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00472 · Cited by 88
Metadata
- Authors
- Holohan, C., Van Schaeybroeck, S., Longley, D. B., & Johnston, P. G.
- Affiliations
- Queen's University Belfast (GB)
- Corresponding author
- Longley, Daniel B.
- Venue
- Nature Reviews Cancer
- Published
- 2013-09-24
- Volume
- 13
- Issue
- 10
- Pages
- 714-726
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2042619042
- Cited by
- 4,681
- References
- 178
- Citations by year
- 2026: 322 · 2025: 358 · 2024: 327 · 2023: 356 · 2022: 364 · 2021: 442 · 2020: 465 · 2019: 460 · 2018: 433 · 2017: 385 · 2016: 342 · 2015: 276 · 2014: 135 · 2013: 4
- FWCI
- 26.69
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Research Portal (Queen's University Belfast) (submittedVersion)
- Funders
- Cancer Research UK (13172, 13721, C212/A13721)
- Public Health Agency (RRG/3261/05)
- Topics
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Keywords
- chemoresistance, targeted therapy, drug target alterations, cell death evasion, predictive biomarkers, patient stratification, high-throughput screening, preclinical models
- MeSH terms
- Adaptation, Physiological, Antineoplastic Agents, Autophagy, Biological Transport, Biotransformation, DNA Damage, DNA Repair, Humans, Models, Biological, Mutation, Neoplasm Proteins, Neoplastic Stem Cells, Drug Design, Gene Expression Regulation, Neoplastic, Apoptosis, ATP-Binding Cassette Transporters, Drug Resistance, Neoplasm, Gene Silencing, Apoptosis Regulatory Proteins, Epithelial-Mesenchymal Transition, Molecular Targeted Therapy, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.